Výsledky vyhledávání

Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib

Autor: Chee Shee Chai, Chong-Kin Liam, Gwo Fuang Ho, O. Po Lin, Mau Ern Poh, Jiunn Liang Tan, Yong Kek Pang, Chee Kuan Wong, Adlinda Alip

Publikováno v: Annals of Oncology. 30:ix167

Background Patients receiving first-line afatinib, gefitinib or erlotinib for epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer develop progression of disease (PD) after an average of 9-13 months. Methods A retrospect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae27917a0c8b6685596ca543f3fe6254
https://doi.org/10.1093/annonc/mdz437.020

Zobrazit plný text záznamu

Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma

Autor: Chong-Kin Liam, Gwo Fuang Ho, Yong Kek Pang, Chee Shee Chai, Adlinda Alip, O. Po Lin, Chee Kuan Wong, Jiunn Liang Tan, Mau Ern Poh

Publikováno v: Annals of Oncology. 30:ix164

Background Afatinib is an irreversible second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) while gefitinib or erlotinib are reversible first-generation EGFR-TKIs. Methods A retrospective analysis of patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f39652d945fb50a20af26097a478709
https://doi.org/10.1093/annonc/mdz437.013

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání